Last reviewed · How we verify
BR790
At a glance
| Generic name | BR790 |
|---|---|
| Sponsor | Jiangxi Qingfeng Pharmaceutical Co. Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer (PHASE1, PHASE2)
- Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors (PHASE1, PHASE2)
- A Phase I Study of BR790 in Subjects With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |